@article {2366,
	title = {Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin},
	journal = {Journal of Inorganic Biochemistry},
	volume = {103},
	number = {4},
	year = {2009},
	note = {ISI Document Delivery No.: 429EUTimes Cited: 8Cited Reference Count: 31Bordbar, Abdol-Khalegh Creagh, A. Louise Mohammadi, Fakhrossadat Haynes, Charles A. Orvig, Chris6th International Vanadium SymposiumJUL 17-19, 2008Lisbon, PORTUGALSp. Iss. SI},
	month = {Apr},
	pages = {643-647},
	type = {Proceedings Paper},
	abstract = {Bis(maltolato)oxovanadium(IV) (BMOV), and its ethylmaltol analog, bis(ethymaltolato)oxovanadium(IV) (BEOV), are candidate insulin-enhancing agents for the treatment of type 2 diabetes mellitus; in mid-2008, BEOV advanced to phase 11 clinical testing. The interactions of BMOV and its inorganic congener, vanadyl Sulfate (VOSO4), with human serum apo-transferrin (hTf) were investigated using differential scanning calorimetry (DSC). Addition of BMOV or VOSO4 to apo-hTf resulted in an increase in thermal stability of both the C- and N-lobes of transferrin as a result of binding to either vanadyl compound. A series of DSC thermograms of hTf Solutions containing different molar ratios of BMOV and VOSO4 were used to determine binding constants: at 25 degrees C the binding constants of BMOV to the C- and N-lobes of apo-hTf were found to be 3 (+/- 1) x 10(5) and 1.8 (+/- 0.7) x 10(5) M-1, respectively. The cot-responding values for VOSO4 were 1.7 (+/- 0.3) x 10(5) and 7 (+/- 2) x 10(4) M-1. The results show that the vanadium species initially presented as either BMOV or VOSO4 had similar affinities for human serum transferrin due to oxidation of solvated vanadyl(IV) prior to complexation to transferrin. Binding of metavanadate (VO3-) was confirmed by DSC and isothermal titration calorimetry (ITC) experiments of the interaction between sodium metavanadate (NaVO3) and hTf. (C) 2008 Elsevier Inc. All rights reserved.},
	keywords = {Apo-transferrin, BINDING, BIS(MALTOLATO)OXOVANADIUM(IV), CHEMISTRY, COMPLEXES, Insulin-enhancing, iron, MALTOL, MOLYBDENUM, NICKEL, RATS, STABILITY, VANADIUM},
	isbn = {0162-0134},
	url = {<Go to ISI>://000264904400022},
	author = {Bordbar, A. K. and Creagh, A. L. and Mohammadi, F. and Haynes, C. A. and Orvig, Chris}
}
@article {2637,
	title = {Vanadium treatment of type 2 diabetes: A view to the future},
	journal = {Journal of Inorganic Biochemistry},
	volume = {103},
	number = {4},
	year = {2009},
	note = {ISI Document Delivery No.: 429EUTimes Cited: 20Cited Reference Count: 41Thompson, Katherine H. Lichter, Jay LeBel, Carl Scaife, Michael C. McNeill, John H. Orvig, Chris6th International Vanadium SymposiumJUL 17-19, 2008Lisbon, PORTUGALSp. Iss. SI},
	month = {Apr},
	pages = {554-558},
	type = {Proceedings Paper},
	abstract = {3-Hydroxy-2-methyl-4-pryone and 2-ethyl 3-hydroxy-4-pyrone (maltol and ethyl maltol, respectively) have proven especially suitable a ligands for vanadyl tons, fit potential insulin enhancing agents for diabetes mellitus. Both bis(maltolato)oxovanadium(IV) (BMOV), and the ethylmaltol analog, bis(ethylmaltolato)oxovanadium(IV) (BEOV), have the desired intermediate stability for pro-drug use, and have undergone extensive pie-clinical testing for safety and efficacy. Pharmacokinetic evaluation indicates a pattern of biodistribution consistent with fairly rapid dissociation and uptake, binding to serum transferrin for systemic circulation and transport to tissues, with preferential uptake in bone. These bis-ligand oxovanadium(IV) (VOL2) compounds have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy. BEOV has now completed Phase I and has advanced to Phase II clinical trials. In the Phase I trial, a ran-e of doses horn 10 mg, to 90 mg BEOV, given orally to non-diabetic volunteers, resulted in no adverse effects, all biochemical parameters remained within normal limits. In the Phase IIa trial, BEOV (AKP-020). 20 mg, daily for 28 clays, per os, in seven type 2 diabetic Subjects, was associated with reductions in fasting blood and glucose and \%HbA1c; improved responses to oral glucose tolerance testing, versus, the observed worsening of diabetic symptoms in the two placebo controls. (C) 2009 Elsevier Inc. All rights reserved.},
	keywords = {BIODISTRIBUTION, bis(ethylmaltolato)oxovanadium(IV), BIS(MALTOLATO)OXOVANADIUM(IV), CHEMISTRY, Diabetes mellitus, IN-VIVO, INSULIN SENSITIVITY, MALTOL, METAL-COMPLEXES, RATS, SERUM, SKELETAL-MUSCLE, SULFATE, VANADIUM},
	isbn = {0162-0134},
	url = {<Go to ISI>://000264904400011},
	author = {Thompson, K. H. and Lichter, J. and Lebel, C. and Scaife, M. C. and McNeill, J. H. and Orvig, Chris}
}
@article {2868,
	title = {RHENIUM(V) AND TECHNETIUM(V) COMPLEXES OF BIDENTATE (0, 0) MONOBASIC 3-OXY-4-PYRONATO AND -4-PYRIDINONATO LIGANDS - X-RAY STRUCTURES OF CIS-BROMOBIS(3-METHYL-2-OXY-4-PYRONATO)OXORHENIUM(V), TETRA-N-BUTYLAMMONIUM TRIBROMO(3-METHYL-2-OXY-4-PYRONATO)OXORHENA},
	journal = {Inorganic Chemistry},
	volume = {32},
	number = {21},
	year = {1993},
	note = {ISI Document Delivery No.: MC686Times Cited: 27Cited Reference Count: 39},
	month = {Oct},
	pages = {4491-4497},
	type = {Article},
	abstract = {{A series of technetium(V) and rhenium(V) complexes of the form [MOXL2], where L is a bidentate (0, 0) monobasic ligand, 2-methyl-3-oxy-4-pyronate (maltolate, ma-) or 1,2-dimethyl-3-oxy-4-pyridinonate (dpp-), and X is a halo ligand},
	keywords = {3-HYDROXY-4-PYRIDINONES, aluminum, CHEMISTRY, CRYSTAL-STRUCTURE, MALTOL, MATRIX, NUCLEAR-MEDICINE, RADIOPHARMACEUTICALS, REACTIVITY, SCHIFF-BASES},
	isbn = {0020-1669},
	url = {<Go to ISI>://A1993MC68600005},
	author = {Luo, H. Y. and Rettig, S. J. and Orvig, Chris}
}
